EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients

Exclusion Criteria

• •Participants were excluded from the study if any of the following criteria apply:
• •Participants who underwent any sinus intranasal surgery (including polypectomy) within 6 months before Visit 1.
• •Participants who had a sino-nasal surgery changing the lateral wall structure of the nose, making impossible the evaluation of NPS.
• •Participants with conditions/concomitant diseases making them non evaluable at Visit 1 or for the primary efficacy endpoint such as: Antrochoanal polyps, Nasal septal deviation that would occlude at least one nostril, Acute sinusitis, nasal infection, or upper respiratory infection.
• •Severe asthma exacerbation requiring treatment with SCS in the last 4 weeks prior to Visit 1 and during screening.
• •Severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the participant's participation in the study
• •Diagnosed with, suspected of, or at high risk of endoparasitic infection, and/or use of antiparasitic drugs within 2 weeks before Visit 1 (screening visit) or during the screening and run-in period.
• •History of human immunodeficiency virus (HIV) infection or positive HIV 1/2 serology at Visit 1 (screening visit).
• •Known or suspected immunodeficiency, including history of invasive opportunistic infections
• •Active malignancy or history of malignancy within 5 years before Visit 1 (screening visit), except completely treated in situ carcinoma of the cervix and completely treated and resolved non metastatic squamous or basal cell carcinoma of the skin.
• •History of systemic hypersensitivity or anaphylaxis to dupilumab and omalizumab, including any excipient
• •Treatment with a live (attenuated) vaccine within 4 weeks before Visit 1 (screening visit).
• •The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.